Myasthenia gravis drug trial halted early – only 6 patients enrolled

NCT ID NCT05132569

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested tolebrutinib, an oral drug, in adults with moderate-to-severe generalized myasthenia gravis. The trial was a Phase 3, double-blind, placebo-controlled study that planned to enroll many participants but was terminated early with only 6 people enrolled. Because it stopped so early, there is no reliable information on whether tolebrutinib helps or is safe for this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tolebrutinib (oral tablet)
What could go wrong: The trial was terminated early with only 6 participants, so no conclusions can be drawn about safety or effectiveness. This drug may not work for myasthenia gravis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

Georgetown University-Site Number:8400008

Washington D.C., District of Columbia, 20007, United States
Harvard Medical School - Brigham and Women's Hospital-Site Number:8400004

Boston, Massachusetts, 02115, United States
Investigational Site Number :1240003

London, Ontario, N6A 5A5, Canada
Investigational Site Number :1240004

Edmonton, Alberta, T6G 2B7, Canada
Investigational Site Number :1560001

Shanghai, 200040, China
Investigational Site Number :1560002

Wuhan, 430030, China
Investigational Site Number :1560003

Chengdu, 610041, China
Investigational Site Number :3480001

Szeged, 6725, Hungary
Investigational Site Number :3480002

Pécs, 7623, Hungary
Investigational Site Number :3800001

Milan, 20132, Italy
Investigational Site Number :3800002

Milan, Lombardy, 20133, Italy
Investigational Site Number :3800003

Roma, 00168, Italy
Investigational Site Number :3800004

Naples, 80131, Italy
Investigational Site Number :3920002

Sagamihara-shi, Kanagawa, 252-0392, Japan
Investigational Site Number :6160001

Zabrze, 41-800, Poland
Investigational Site Number :7240003

L'Hospitalet de Llobregat, Catalunya [Cataluña], 08907, Spain
Investigational Site Number :7240005

Madrid, Madrid, Comunidad de, 28046, Spain
Investigational Site Number :8260001

Liverpool, L9 7LJ, United Kingdom
Investigational Site Number :8260002

Exeter, Devon, EX2 5DW, United Kingdom
Neurology Center of San Antonio, PA-Site Number:8400009

San Antonio, Texas, 00000, United States
SFM Clinical Research, LLC-Site Number:8400006

Boca Raton, Florida, 33487, United States
University of South Florida Health- Morsani Center for Advanced Healthcare-Site Number:8400001

Tampa, Florida, 33612-6601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.